Why RoslinCT

Spun out from the Roslin Institute, home of “Dolly” the cloned sheep, RoslinCT has been at the forefront of innovation, supporting partners from early process development through commercialization, including the first CRISPR-based stem cell therapy, CASGEVY™

Adaptive approach to partner relationships, customized and differentiated solutions for technology transfer and cGMP manufacturing that meet our partners’ unique requirements

30+ years of individual cell therapy industry experience from the leadership team, deep scientific expertise throughout, supported by a robust Scientific Advisory Board and deep resources from GHO Capital

11 PD/AD labs, 22 transatlantic, purpose-built cGMP processing suites capable of meeting both US and EU regulatory requirements for clinical and commercial manufacturing

Supporting autologous and allogeneic products across a variety of cell types and platforms, including iPSC, CAR-T, NK, TCR, Treg, TIL, and MSC, with a 100% tech transfer success rate and over 200 cGMP batches produced for various indications

With a strong history of FDA, MHRA, and EMA clearances and successful third-party audits, RoslinCT ensures global clinical and commercial manufacturing with adaptable cGMP compliance systems and precise QC analytical capabilities, delivering reliability and unmatched quality

Integrated software solutions enable electronic batch records supporting real-time monitoring, testing and release of products, as well as management of inbound and outbound logistics

Pioneers in stem cell-based services and as one of the first in the world to produce clinical-grade human pluripotent cells, with extensive experience in a range of reprogramming technologies, gene editing, expansion strategies, and all aspects of quality control testing